This study aims to estimate immunohistochemical expression of IL-4, IL-17, and CD-163 as well as study of IL6-572 C/G gene polymorphism in chronic HCV and HCC on top of HCV to determine the possibility of their use as therapeutic targets for chronic HCV to control progression to cirrhosis then to HCC. This evidence concerns the gene IL6 and hepatocellular carcinoma.